Nicholas Investment Partners, LP Krystal Biotech, Inc. Transaction History

Nicholas Investment Partners, LP

$900 Million
Q3 2024

A detailed history of Nicholas Investment Partners, LP transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Nicholas Investment Partners, LP holds 18,807 shares of KRYS stock, worth $3.02 Million. This represents 0.38% of its overall portfolio holdings.

Number of Shares

18,807

Previous 17,327 8.54%

Holding current value

$3.02 Million

Previous $3.18 Million 7.51%

% of portfolio

0.38%

Previous 0.38%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$174.7 - $213.66 $258,555 - $316,216	1,480 Added 8.54%	18,807 $3.42 Million
Q2 2024 Aug 07, 2024	BUY	$153.12 - $183.64 $2.65 Million - $3.18 Million	17,327 New	17,327 $3.18 Million
Q4 2023 Feb 07, 2024	SELL	$96.0 - $128.29 $29.4 Million - $39.3 Million	-306,538 Reduced 86.2%	49,073 $6.09 Million
Q3 2023 Nov 13, 2023	SELL	$108.51 - $130.22 $2.1 Million - $2.52 Million	-19,340 Reduced 5.16%	355,611 $41.3 Million
Q2 2023 Aug 09, 2023	BUY	$78.48 - $130.32 $18,285 - $30,364	233 Added 0.06%	374,951 $44 Million
Q1 2023 May 11, 2023	BUY	$72.39 - $84.27 $7.79 Million - $9.07 Million	107,629 Added 40.3%	374,718 $30 Million
Q4 2022 Feb 10, 2023	BUY	$63.14 - $79.9 $2.85 Million - $3.6 Million	45,063 Added 20.3%	267,089 $21.2 Million
Q3 2022 Nov 14, 2022	SELL	$64.85 - $82.4 $379,437 - $482,122	-5,851 Reduced 2.57%	222,026 $15.5 Million
Q2 2022 Aug 10, 2022	SELL	$48.93 - $73.47 $41,835 - $62,816	-855 Reduced 0.37%	227,877 $15 Million
Q1 2022 May 10, 2022	BUY	$51.99 - $72.11 $1.95 Million - $2.7 Million	37,421 Added 19.56%	228,732 $15.2 Million
Q4 2021 Feb 14, 2022	SELL	$39.81 - $88.24 $2.61 Million - $5.79 Million	-65,564 Reduced 25.52%	191,311 $13.4 Million
Q3 2021 Nov 15, 2021	SELL	$52.01 - $71.77 $2.94 Million - $4.06 Million	-56,579 Reduced 18.05%	256,875 $13.4 Million
Q2 2021 Aug 10, 2021	BUY	$62.14 - $81.82 $544,657 - $717,152	8,765 Added 2.88%	313,454 $21.3 Million
Q1 2021 May 14, 2021	BUY	$59.42 - $85.46 $4.23 Million - $6.08 Million	71,146 Added 30.46%	304,689 $23.5 Million
Q4 2020 Feb 11, 2021	BUY	$40.64 - $61.38 $451,957 - $682,606	11,121 Added 5.0%	233,543 $14 Million
Q3 2020 Nov 13, 2020	BUY	$37.76 - $48.49 $6.91 Million - $8.87 Million	182,914 Added 462.98%	222,422 $9.58 Million
Q2 2020 Aug 12, 2020	SELL	$37.03 - $60.0 $1.57 Million - $2.54 Million	-42,408 Reduced 51.77%	39,508 $1.64 Million
Q1 2020 May 13, 2020	BUY	$35.02 - $65.64 $262,579 - $492,168	7,498 Added 10.08%	81,916 $3.54 Million
Q4 2019 Feb 13, 2020	SELL	$33.17 - $65.23 $1.17 Million - $2.31 Million	-35,409 Reduced 32.24%	74,418 $4.12 Million
Q3 2019 Nov 13, 2019	SELL	$34.72 - $51.3 $13,957 - $20,622	-402 Reduced 0.36%	109,827 $3.81 Million
Q2 2019 Aug 09, 2019	SELL	$27.2 - $41.2 $27,091 - $41,035	-996 Reduced 0.9%	110,229 $4.44 Million
Q1 2019 May 15, 2019	SELL	$19.86 - $32.9 $392,254 - $649,807	-19,751 Reduced 15.08%	111,225 $3.66 Million
Q4 2018 Feb 14, 2019	BUY	$15.03 - $25.38 $1.97 Million - $3.32 Million	130,976 New	130,976 $2.72 Million

Others Institutions Holding KRYS

# of Institutions

310

Shares Held

24.3M

Call Options Held

483K

Put Options Held

364K

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.13B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nicholas Investment Partners, LP, based on Form 13F filings with the SEC.

News

Stay updated on Nicholas Investment Partners, LP with notifications on news.

Account

Nicholas Investment Partners, LP Krystal Biotech, Inc. Transaction History